Skip to main content

Site notifications

AQUIPTA (Allergan Australia Pty Ltd)

Product name
AQUIPTA
Date registered
Evaluation commenced
Decision date
Approval time
211 (255 working days)
Active ingredients
atogepant
Registration type
NCE/NBE
Indication

AQUIPTA is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month

Help us improve the Therapeutic Goods Administration site